Mauna Kea Technologies Granted 14th US Patent

Mauna Kea Technologies, a pioneer in confocal laser endomicroscopic imaging, announces the acquisition of its 14th U.S. patent. This patent strengthens its portfolio in artificial intelligence (AI) applied to medical imaging. This initiative underscores its ongoing commitment to technological innovation.

The patent concerns the real-time enhancement of image sequences using AI, strengthening collaboration between doctors and machines. This development amplifies the potential of the Cellvizio® platform, used worldwide for medical diagnosis.

This progress is part of a series of innovations illustrating Mauna Kea's crucial role in AI research and development. The company is positioning itself as a key player and preferred partner for the design of high-value solutions.

Sacha Loiseau, CEO, emphasizes the importance of this addition to the company's technological base, aimed at making the Cellvizio platform more powerful and intuitive for all partners involved.